Trial
NCT01018953
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ipsen
Collaborators
—
Condition
Carcinoid Syndrome
Intervention
BIM 23A760
Why stopped
Preliminary data from study NCT00994214 do not support expected inhibition of GH and IGF-1
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-20